Project Background
A US-based biotechnology team was developing a BRD4 degrader for oncology-related targeted protein degradation research. The molecule contained a triazole-containing PEG-alkyl hybrid linker, a thienodiazepine warhead, and a CRBN ligand. The client had produced milligram quantities internally, but the original route required multiple low-yield coupling steps and generated polar impurities that were difficult to remove. They needed BOC Sciences to redesign the synthetic route and manufacture sufficient material for SAR and in vitro degradation testing.
Technical Challenges
The key challenges included low conversion in the final coupling step, partial degradation of the CRBN-binding moiety under basic conditions, poor solubility of the late-stage intermediate, and co-elution of linker-derived impurities during reverse-phase purification.
BOC Sciences Solutions
- Route Redesign: We changed the assembly order by first preparing a purified warhead-linker intermediate and then coupling it with an activated CRBN ligand derivative under milder conditions.
- Linker Intermediate Control: Three linker activation strategies were compared, including azide-alkyne cycloaddition, activated ester coupling, and amide coupling. The click-based approach delivered the cleanest intermediate profile and minimized side reactions.
- Purification Optimization: We screened gradient conditions, mobile phase modifiers, and column chemistries to separate the final degrader from polar linker byproducts and closely related incomplete conjugates.
Project Outcomes
BOC Sciences evaluated 18 route and purification conditions and selected a reproducible route that increased isolated yield from below 8% to 31% for the final assembly stage. The optimized BRD4 PROTAC was delivered as a well-characterized research batch with confirmed mass, NMR assignment, and HPLC profile. The material enabled the client to complete dose-response degradation studies and identify two linker-modified analogs with improved cellular DC50 values.
Project Background
A European pharmaceutical discovery group was working on a covalent BTK PROTAC containing an acrylamide warhead, a semi-rigid piperazine linker, and a VHL ligand. The compound showed promising degradation activity in early screening, but repeated manufacturing attempts produced inconsistent purity and variable biological results. The client asked BOC Sciences to troubleshoot the route, manufacture a new batch, and propose a more reliable analog production strategy.
Technical Challenges
The acrylamide warhead was sensitive to nucleophilic impurities, the VHL ligand intermediate required strict stereochemical preservation, and the final molecule showed aggregation behavior during concentration. Several impurities had similar UV response and retention times, complicating routine analytical monitoring.
BOC Sciences Solutions
- Warhead Protection Strategy: We delayed installation of the acrylamide warhead until the final synthetic stage, reducing exposure to nucleophilic reagents and minimizing premature side reactions.
- Stereochemistry Monitoring: Chiral HPLC and NMR analysis were introduced at key intermediate stages to confirm preservation of VHL ligand stereochemistry before final assembly.
- Aggregation-Aware Isolation: Solvent exchange, concentration temperature, and lyophilization conditions were optimized to reduce aggregation and improve redissolution behavior for biological testing.
Project Outcomes
BOC Sciences screened 11 solvent and isolation conditions, identified two impurity sources, and manufactured a consistent BTK PROTAC research batch with improved analytical clarity. The final material showed stable handling performance in DMSO stock preparation and supported reproducible BTK degradation assessment. The optimized manufacturing logic was then applied to six follow-up analogs, helping the client compare linker rigidity and warhead positioning with higher confidence.
Bridges Molecular Design and Biological Validation
